ESO Observatory: What will change for men with advanced prostate cancer in the next 24 months?
Not eligible for ESCO credits
10.03.2017
St. Gallen, Switzerland
OBSERVATORY
Description
The European School of Oncology is pleased to announce the ESO Advanced Prostate Cancer Observatory which will be held during the Advanced Prostate Cancer Conference (APCC) on 10 March 2017 in St. Gallen, Switzerland.
AIMS AND OBJECTIVES
ESO Observatories are high level sessions organized during major international congresses with the aim of providing the audience with updated and unbiased information on a given topic. An ESO Observatory concentrates on a forecast given by a panel of experts of what is expected to happen in their own field in the coming period. The panel, that includes distinguished clinicians and scientists and a patient advocate, provides their forecast in the form of take-home concise message with short presentations followed by discussion.
General information
Attendance is granted to all participants registered to the APCC conference (9-11 March 2017, Einstein St. Gallen Hotel, St. Gallen, Switzerland).
http://www.prostatecancerconsensus.org
For further information on the Observatory, please contact cmelcher@eso.net
Faculty list
PANEL
H. Beltran, Weill Cornell Medical College, New York, US
R. Borges Dos Reis, Ribeirao Preto Medical School, University of Sao Paulo, BR
C. Drake, Johns Hopkins University, Baltimore, US
S. Gillessen, Cantonal Hospital, S. Gallen, CH
G. Kramer, University Klinik Vienna, AT
C. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, US
O. Sharp, Movember Foundation, London, UK
C. Sternberg, Ospedale San Camillo Forlanini, Rome, IT
R. Valdagni, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
T. Wiegel, University Hospital Ulm, DE
Programme
PROGRAMME
Friday, 10 March 2017
17:00-18:30
ESO Observatory:
What will change for men with advanced prostate cancer in the next 24 months?
Chairs: R. Valdagni, IT and S. Gillessen, CH
• Perspective on molecular characterization (H. Beltran, US)
• Perspective on imaging (PET and MRI) (G. Kramer, AT)
• Perspective on endocrine and chemotherapy agents (C. Sternberg, IT)
• Perspective on immunotherapy (C. Drake, US)
• Perspective on novel agents (including PARP inhibitors) (C. Logothetis, US)
• Perspective on radiation therapy (T. Wiegel, DE)
• Perspective on surgery (R. Borges Dos Reis, BR)
• Patients’ perspective (O. Sharp, UK)
• Panel discussion and conclusions